Listed publications (for updated information click on the link to PubMed)

  1.  Rodrigues, R.M., Cuddington, B.and K. L. Mossman*. (2009) Bovine herpesvirus type 1 as a novel oncolytic virus.  Cancer Gene Therapy 17(5): 344-355.

  2. Sobol, P. T., Boudreau, J. E., Stephenson, K., Wan, Y., Lichty, B. D. and K. L. Mossman*. (2011) Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Molecular Therapy 19(2): 335-344. Article mentioned on cover of journal.

  3. DeSilva, A., Wuest, M., Wang, M., Hummel, J.,Mossman, K., Wuest, F. and M. M. Hitt.  (2012) Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [18F]FDG and [18F]FLT.  Am J Nucl Med Mol Imaging 2(1): 88-98. 

  4. Workenhe, S., Cummings, D., Pol, J., Lichty, B. and K. L. Mossman*.  (2013) Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunology Research 1(5): 1-11. 

  5. Workenhe, S.T.and K. L. Mossman*.  (2013) Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.  Oncoimmunology 2(12): e27138.

  6. Cuddington, B., Dyer, A., Workenhe, S. and K. L. Mossman*. (2013)  Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer initiating cells irrespective of tumor subtype. Cancer Gene Therapy 20(5): 282-289. 

  7. Workenhe, S., Simmons, G., Pol, J., Lichty, B., Halford, W. and K. L. Mossman*. (2014) Immunogenic HSV mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Molecular Therapy 22(1):  123-131. 

  8. Workenhe, S. and K. L. Mossman*. (2014) Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Molecular Therapy 22(2): 251-256.

  9. Cuddington, B.and K. L. Mossman*.(2014) Permissiveness of human cancer cells to oncolytic Bovine herpes virus type 1 is mediated in part by KRAS activity.  Journal of Virology, 88(12): 6885-95. 

  10. Nellimarla, S. and K. L. Mossman*.(2014) Extracellular dsRNA:  Its function and Mechanism of cellular uptake (Invited Review). Journal of Interferon and Cytokine Research. 34(6): 419-426.

  11. Taylor KE, andK. L. Mossman*.(2014). Interference in innate immunity: another dimension in ICP0 multifunctionality. British Journal of Virology. 1(2): 72-78.

  12. Collins, Sand K. L. Mossman*.(2014). Danger, Diversity and Priming in Innate Antiviral Immunity (Invited Review). Cytokine and Growth Factor Reviews. 25: 525-531.

  13. McComb S, Cessford E, Alturki NA, Joseph J, Shutinoski B, Starteck JB, Gamero AM, Mossman KL, Sad S. (2014). Type-I Interferon Signalling Through ISGF3 Complex Is Required For Sustained Rip3 Activation and Necroptosis in Macrophages. Proceedings of the National Academy of Sciences. 111(31): 3206-13.

  14. Cuddington BPand K. L. Mossman*.(2014). Identifying Roadblocks to Successful Oncolytic Virotherapy: What are they and how do we approach them? (Invited Review) Future Virology. 9(8): 695-697.

  15. Oliver Kepp,...Mossman, K,…Workenhe, S,... et. al. (2014). Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3(9): e955691.

  16. Cuddington BP, Verschoor M, and K. L. Mossman*.(2014). Cotton rats as a model for the pre-clinical evaluation of oncolytic viruses. Journal of Visual Experimentation. 93: e52232.

  17. Ng, D, Maitre, B, Cumming, D, Lin, A, Ward, LA, Rahbar, Mossman, K, Ohashi PS, Gommerman JL*. (2015) A Lymphotoxin/Type I IFN axis programs CD8+ T cells to infiltrate a self-tissue and propagate immunopathology. Journal of Immunology 195(10):4650-9.

  18. Nellimarla, S., Baid, K., Loo, YM, Gale, M, Bowdish, DM and Mossman, KL*. (2015) Class A scavenger receptor-mediated dsRNA internalization is independent of innate antiviral signaling and does not require PI3K activity. Journal of Immunology 195(8): 3858-65.

  19. Taylor, KEand Mossman, K.L*.(2015) Cellular protein WDR11 interacts with specific herpes simplex virus proteins at the trans-Golgi network to promote virus replication. Journal of Virology 89(19): 9841-52.

  20. Cunha, CW#, Taylor, KE#, Pritchard, SM, Delboy, MG, Sari TK. Aguilar HC, Mossman KL*and Nicola AV*(2015) Widely used herpes simplex virus ICP0 deletion mutant strain dl1403 and its derivative viruses do not express glycoprotein C due to a secondary mutation in the gC gene. PLoS ONE 10(7): e0131129. 

  21. Cuddington, BP, Verschoor, M, Ashkar, A and Mossman, K.L*.(2015). Enhanced Efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma. Molecular Therapy - Oncolytics. 1: 15004.

  22. Mossman, K.L.and S.K. Weller*. (2015) HSV cheats the executioner. Cell Host & Microbe 17(2): 148-51.

  23. Workenhe, S.T., Verschoor, M. and K. L. Mossman*.  (2015) The role of oncolytic virus immunotherapies to subvert cancer immune evasion.  Future Oncology 11 (4): 675-89. 

  24. Cuddington, B.P. and K. L. Mossman*.(2015) Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic. Current Opinion in Virology 13: 11-16. 

  25. Wetzel J, Herrmann S, Swapna LS, Prusty D, Peter AT, Kono M, Saini S, Nellimarla S, Wong TW, Wilcke L, Ramsay O, Cabrera A, Biller L, Heincke D, Mossman K, Spielmann T, Ungermann C, Parkinson J, Gilberger TW. (2015) The role of palmitoylation for protein recruitment to the inner membrane complex of the malaria parasite.  Journal of Biological Chemistry 290(3): 1712-28.

  26. Workenhe STand Mossman KL*.(2016) Genome-wide lentiviral shRNA screen identifies Serine-arginine Rich Splicing Factor 2 as a determinant of oncolytic virus activity in breast cancer cells. Oncogene 35(19): 2465-74.

  27. Duerr, CU, McCarthy CDA, MindtB, Rubio, M, Meli, AP, Eva, MM, Mossman, KL, Malo, D, Gamero AM, Vidal SM, King, IL, Sarfati, M, Fritz, JH* (2016) Type I interferon restricts type 2 immunopathology through regulation of group 2 innate lymphoid cells. Nature Immunology 17(1): 65-75.

  28. HareDN, Collins SE, Mukherjee S, Loo YM, Gale M Jr, Janssen LJ, MossmanKL* (2016) Membrane perturbation-associated Ca2+ signaling and incoming genome sensing are required for the host response to low-level enveloped virus particle entry. Journal of Virology 90(6): 3018-27.

  29. Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ES, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD*. (2016) S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. Nature Immunology 17(5): 514-22.

  30. HareDN, Collins SE, Cuddington B, MossmanKL* (2016). The importance of physiologically relevant cell lines for studying virus-host interactions. Viruses8(11): pii: E297.

  31. Schulz KS, MossmanKL* (2016). Viral evasion strategies in type I IFN signaling: a summary of recent developments.  Frontiers in Immunology 7: article 498.

  32. Torre S, Polyak MJ, Langlais D, Fodil N, Kennedy JM, Radovanovic I, Berghout J, Leiva-Torres GA, Krawczyk CM, Ilangumaran S, Mossman K, Liang C, Knobeloch KP, Healy LM, Antel J, Arbour N, Prat A, Majewski J, Lathrop M, Vidal SM, Gros P*. (2017) USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. Nature Immunology 18(1): 54-63.

  33. Kirkham CL, Aguilar OA, Yu T, Tanaka M, Mesci A, Chu K-L, Fina JH, Mossman KL, Bremner R, Allan DSJ, Carlyle JR*. (2017) Interferon-dependent induction of Clr-b during MCMV infection protects bystander cells from NK cells via NKR-P1B-mediated inhibition. Journal of Innate Immunity 9(4): 343-358.

  34. Lee A, Chen B, Chew M, Barra M, Shenouda M, Nham T, Van Rooijen N, Jordana M, Mossman K, Schreiber R, Mack M, Ashkar A*. (2017) Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during mucosal viral infection. Journal of Experimental Medicine 214(4): 1153-1167. 

  35. Auger JP, Santinon A, Roy D, Mossman K, Xu J, Segura M, Gottschalk M*. (2017) Type I interferon induced by Streptococcus suis serotype 2 is strain-dependent and may be beneficial for host survival. Frontiers in Immunology 8: article 1039.

  36. Van Vloten JP, Workenhe ST, Wootton SK, Mossman KL*, Bridle BW*. (2018) Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. Journal of Immunology 200(2): 450-458.

  37.  

  38. Baid K, Nellimarla S, Huynh A, Guarne A, Collins SE, Mossman KL*. (2018) Direct binding of extracellular nucleic acids by the class A scavenger receptor collagenous domain. Immunology and Cell Biology 96(9):922-934 

  39. Banerjee A, Baid K,Mossman K*. (2018) “One Health” keeps humans one step ahead of the microbes. (2018)  The Conversation (online resource).

  40. Banerjee, A, Perez-Lopez, E, Mossman K*(2018). Commentary:  Phyllostomid bat microbiome composition is associated to host phylogeny and feeding strategies. Frontiers in Microbiology https://doi.org/10.3389/fmicb.2018.02863

  41. Banerjee, A,Misra, V, Mossman K. (2018). Viruses can cause global pandemics, but where did the first virus come from? The Conversation (online resource).

  42. Zakaria C, Sean P, Hoang HD, Watson M, Jia JJ, Hearnden J, Yanagiya A, Pearl D, Arguello M, Robichaud N, Graber TE, Fonseca BD, Siddiqui N, Jaramillo M, Diallo JS, LeBoeuf F, Mossman K, Sonenberg N, Alain T. (2018). Active-Site mTOR Inhibitors Augment HSV1-dICP0 Infection in Cancer Cells via dysregulated eIF4E/4E-BP axis. PLoS Pathogens 14(8): e1007264.

  43. Pol J, Levesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzi L. (2018). Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology doi.org/10.1080/2162402X.2018.1503032

  44. Vahedi F, Lee AJ, Collins SE, Chew ME, Lusty E, Chen B, Dubey A, Richards C, Feld JJ, Russell R, Mossman KLand Ashkar AA. (2018). IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. Cytokine S1043-4666(18)30254-0[Epub ahead of print]

  45. Banerjee A,Kulcsar K, Misra V, Frieman M, Mossman K*. (2019) Bats and coronaviruses. Viruses 11, 41, doi:10.3390/v11010041

  46. Martin N, Roy D, Workenhe ST, van den Wollenberg D, Hoeben R, Mossman K, Bell J, and Bourgeois-Daigneault M-C*. (2019) Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports [In Press]

  47. Davola M, Mossman K*. (2019) Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? OncoImmunology [Under review]

  48. Workenhe ST, Bakhshinyan D, Wei J, MacNeill, KL, Nguyen A, Li D, Wan Y, Wang X, Bramson JL, Mossman KL*. (2019) Therapy-induced necroptosis renders autochthonous mammary tumors susceptible to checkpoint blockade immunotherapy. Immunity [Submitted]. Rodrigues, R.M., Cuddington, B.and K. L. Mossman*. (2009) Bovine herpesvirus type 1 as a novel oncolytic virus. Cancer Gene Therapy 17(5): 344-355.

  49. Sobol, P. T., Boudreau, J. E., Stephenson, K., Wan, Y., Lichty, B. D. and K. L. Mossman*. (2011) Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Molecular Therapy 19(2): 335-344. Article mentioned on cover of journal.

  50. DeSilva, A., Wuest, M., Wang, M., Hummel, J.,Mossman, K., Wuest, F. and M. M. Hitt. (2012) Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [18F]FDG and [18F]FLT. Am J Nucl Med Mol Imaging 2(1): 88-98.

  51. Workenhe, S., Cummings, D., Pol, J., Lichty, B. andK. L. Mossman*. (2013) Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunology Research 1(5): 1-11.

  52. Workenhe, S.T.and K. L. Mossman*. (2013) Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology 2(12): e27138.

  53. Cuddington, B., Dyer, A., Workenhe, S. and K. L. Mossman*. (2013) Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer initiating cells irrespective of tumor subtype. Cancer Gene Therapy 20(5): 282-289.

  54. Workenhe, S., Simmons, G., Pol, J., Lichty, B., Halford, W. and K. L. Mossman*. (2014) Immunogenic HSV mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Molecular Therapy 22(1): 123-131.

  55. Workenhe, S. and K. L. Mossman*. (2014) Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Molecular Therapy 22(2): 251-256.

  56. Cuddington, B.and K. L. Mossman*.(2014) Permissiveness of human cancer cells to oncolytic Bovine herpes virus type 1 is mediated in part by KRAS activity. Journal of Virology, 88(12): 6885-95.

  57. Nellimarla, S. and K. L. Mossman*.(2014) Extracellular dsRNA: Its function and Mechanism of cellular uptake (Invited Review). Journal of Interferon and Cytokine Research. 34(6): 419-426.

  58. Taylor KE, andK. L. Mossman*.(2014). Interference in innate immunity: another dimension in ICP0 multifunctionality. British Journal of Virology. 1(2): 72-78.

  59. Collins, Sand K. L. Mossman*.(2014). Danger, Diversity and Priming in Innate Antiviral Immunity (Invited Review). Cytokine and Growth Factor Reviews. 25: 525-531.

  60. McComb S, Cessford E, Alturki NA, Joseph J, Shutinoski B, Starteck JB, Gamero AM, Mossman KL, Sad S. (2014). Type-I Interferon Signalling Through ISGF3 Complex Is Required For Sustained Rip3 Activation and Necroptosis in Macrophages. Proceedings of the National Academy of Sciences. 111(31): 3206-13.

  61. Cuddington BPand K. L. Mossman*.(2014). Identifying Roadblocks to Successful Oncolytic Virotherapy: What are they and how do we approach them? (Invited Review) Future Virology. 9(8): 695-697.

  62. Oliver Kepp,...Mossman, K,…Workenhe, S,... et. al. (2014). Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3(9): e955691.

  63. Cuddington BP, Verschoor M, and K. L. Mossman*.(2014). Cotton rats as a model for the pre-clinical evaluation of oncolytic viruses. Journal of Visual Experimentation. 93: e52232

  64. Ng, D, Maitre, B, Cumming, D, Lin, A, Ward, LA, Rahbar, Mossman, K, Ohashi PS, Gommerman JL*. (2015) A Lymphotoxin/Type I IFN axis programs CD8+ T cells to infiltrate a self-tissue and propagate immunopathology. Journal of Immunology 195(10):4650-9.

  65. Nellimarla, S., Baid, K., Loo, YM, Gale, M, Bowdish, DM and Mossman, KL*. (2015) Class A scavenger receptor-mediated dsRNA internalization is independent of innate antiviral signaling and does not require PI3K activity. Journal of Immunology 195(8): 3858-65.

  66. Taylor, KEand Mossman, K.L*.(2015) Cellular protein WDR11 interacts with specific herpes simplex virus proteins at the trans-Golgi network to promote virus replication. Journal of Virology 89(19): 9841-52.

  67. Cunha, CW#, Taylor, KE#, Pritchard, SM, Delboy, MG, Sari TK. Aguilar HC, Mossman KL*and Nicola AV*(2015) Widely used herpes simplex virus ICP0 deletion mutant strain dl1403 and its derivative viruses do not express glycoprotein C due to a secondary mutation in the gC gene. PLoS ONE 10(7): e0131129.

  68. Cuddington, BP, Verschoor, M, Ashkar, A and Mossman, K.L*.(2015). Enhanced Efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma. Molecular Therapy - Oncolytics. 1: 15004.

  69. Mossman, K.L.and S.K. Weller*. (2015) HSV cheats the executioner. Cell Host & Microbe 17(2): 148-51.

  70. Workenhe, S.T., Verschoor, M. and K. L. Mossman*. (2015) The role of oncolytic virus immunotherapies to subvert cancer immune evasion. Future Oncology 11 (4): 675-89.

  71. Cuddington, B.P. and K. L. Mossman*.(2015) Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic. Current Opinion in Virology 13: 11-16.

  72. Wetzel J, Herrmann S, Swapna LS, Prusty D, Peter AT, Kono M, Saini S, Nellimarla S, Wong TW, Wilcke L, Ramsay O, Cabrera A, Biller L, Heincke D, Mossman K, Spielmann T, Ungermann C, Parkinson J, Gilberger TW. (2015) The role of palmitoylation for protein recruitment to the inner membrane complex of the malaria parasite. Journal of Biological Chemistry 290(3): 1712-28.

  73. Workenhe STand Mossman KL*.(2016) Genome-wide lentiviral shRNA screen identifies Serine-arginine Rich Splicing Factor 2 as a determinant of oncolytic virus activity in breast cancer cells. Oncogene 35(19): 2465-74.

  74. Duerr, CU, McCarthy CDA, MindtB, Rubio, M, Meli, AP, Eva, MM, Mossman, KL, Malo, D, Gamero AM, Vidal SM, King, IL, Sarfati, M, Fritz, JH* (2016) Type I interferon restricts type 2 immunopathology through regulation of group 2 innate lymphoid cells. Nature Immunology 17(1): 65-75.

  75. HareDN, Collins SE, Mukherjee S, Loo YM, Gale M Jr, Janssen LJ, MossmanKL* (2016) Membrane perturbation-associated Ca2+ signaling and incoming genome sensing are required for the host response to low-level enveloped virus particle entry. Journal of Virology 90(6): 3018-27.

  76. Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ES, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD*. (2016) S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. Nature Immunology 17(5): 514-22.

  77. HareDN, Collins SE, Cuddington B, MossmanKL* (2016). The importance of physiologically relevant cell lines for studying virus-host interactions. Viruses8(11): pii: E297.

  78. Schulz KS, MossmanKL* (2016). Viral evasion strategies in type I IFN signaling: a summary of recent developments. Frontiers in Immunology 7: article 498.

  79. Torre S, Polyak MJ, Langlais D, Fodil N, Kennedy JM, Radovanovic I, Berghout J, Leiva-Torres GA, Krawczyk CM, Ilangumaran S, Mossman K, Liang C, Knobeloch KP, Healy LM, Antel J, Arbour N, Prat A, Majewski J, Lathrop M, Vidal SM, Gros P*. (2017) USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. Nature Immunology 18(1): 54-63.

  80. Kirkham CL, Aguilar OA, Yu T, Tanaka M, Mesci A, Chu K-L, Fina JH, Mossman KL, Bremner R, Allan DSJ, Carlyle JR*. (2017) Interferon-dependent induction of Clr-b during MCMV infection protects bystander cells from NK cells via NKR-P1B-mediated inhibition. Journal of Innate Immunity 9(4): 343-358.

  81. Lee A, Chen B, Chew M, Barra M, Shenouda M, Nham T, Van Rooijen N, Jordana M, Mossman K, Schreiber R, Mack M, Ashkar A*. (2017) Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during mucosal viral infection. Journal of Experimental Medicine 214(4): 1153-1167.

  82. Auger JP, Santinon A, Roy D, Mossman K, Xu J, Segura M, Gottschalk M*. (2017) Type I interferon induced by Streptococcus suis serotype 2 is strain-dependent and may be beneficial for host survival. Frontiers in Immunology 8: article 1039.

  83. Van Vloten JP, Workenhe ST, Wootton SK, Mossman KL*, Bridle BW*. (2018) Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. Journal of Immunology 200(2): 450-458.

  84. Baid K, Nellimarla S, Huynh A, Guarne A, Collins SE, Mossman KL*. (2018) Direct binding of extracellular nucleic acids by the class A scavenger receptor collagenous domain. Immunology and Cell Biology 96(9):922-934

  85. Banerjee A,Baid K,Mossman K*. (2018) “One Health” keeps humans one step ahead of the microbes. (2018) The Conversation (online resource).

  86. Banerjee, A, Perez-Lopez, E, Mossman K*(2018). Commentary: Phyllostomid bat microbiome composition is associated to host phylogeny and feeding strategies. Frontiers in Microbiology https://doi.org/10.3389/fmicb.2018.02863

  87. Banerjee, A,Misra, V, Mossman K. (2018). Viruses can cause global pandemics, but where did the first virus come from? The Conversation (online resource).

  88. Zakaria C, Sean P, Hoang HD, Watson M, Jia JJ, Hearnden J, Yanagiya A, Pearl D, Arguello M, Robichaud N, Graber TE, Fonseca BD, Siddiqui N, Jaramillo M, Diallo JS, LeBoeuf F, Mossman K, Sonenberg N, Alain T. (2018). Active-Site mTOR Inhibitors Augment HSV1-dICP0 Infection in Cancer Cells via dysregulated eIF4E/4E-BP axis. PLoS Pathogens 14(8): e1007264.

  89. Pol J, Levesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzi L. (2018). Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology doi.org/10.1080/2162402X.2018.1503032

  90. Vahedi F, Lee AJ, Collins SE, Chew ME, Lusty E, Chen B, Dubey A, Richards C, Feld JJ, Russell R, Mossman KLand Ashkar AA. (2018). IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. Cytokine S1043-4666(18)30254-0[Epub ahead of print]

  91. Banerjee A,Kulcsar K, Misra V, Frieman M, Mossman K*. (2019) Bats and coronaviruses. Viruses 11, 41, doi:10.3390/v11010041

  92. Martin N, Roy D, Workenhe ST, van den Wollenberg D, Hoeben R, Mossman K, Bell J, and Bourgeois-Daigneault M-C*. (2019) Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer. Scientific Reports [In Press]

  93. Davola M, Mossman K*. (2019) Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? OncoImmunology [Under review]

  94. Workenhe ST, Bakhshinyan D, Wei J, MacNeill, KL, Nguyen A, Li D, Wan Y, Wang X, Bramson JL, Mossman KL*. (2019) Therapy-induced necroptosis renders autochthonous mammary tumors susceptible to checkpoint blockade immunotherapy. Immunity [Submitted].